CO2022012207A2 - Inhaladores de dosis medida presurizada que comprenden una formulación farmacéutica amortiguada - Google Patents

Inhaladores de dosis medida presurizada que comprenden una formulación farmacéutica amortiguada

Info

Publication number
CO2022012207A2
CO2022012207A2 CONC2022/0012207A CO2022012207A CO2022012207A2 CO 2022012207 A2 CO2022012207 A2 CO 2022012207A2 CO 2022012207 A CO2022012207 A CO 2022012207A CO 2022012207 A2 CO2022012207 A2 CO 2022012207A2
Authority
CO
Colombia
Prior art keywords
metered dose
pressurized metered
pharmaceutical formulation
dose inhalers
buffered pharmaceutical
Prior art date
Application number
CONC2022/0012207A
Other languages
English (en)
Inventor
Enrico Zambelli
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of CO2022012207A2 publication Critical patent/CO2022012207A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D127/00—Coating compositions based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Coating compositions based on derivatives of such polymers
    • C09D127/02—Coating compositions based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Coating compositions based on derivatives of such polymers not modified by chemical after-treatment
    • C09D127/12—Coating compositions based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Coating compositions based on derivatives of such polymers not modified by chemical after-treatment containing fluorine atoms
    • C09D127/18—Homopolymers or copolymers of tetrafluoroethene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0238—General characteristics of the apparatus characterised by a particular materials the material being a coating or protective layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Materials Engineering (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se relaciona de manera general con una formulación en aerosol que comprende formoterol y dipropionato de beclometasona, la formulación está contenida en una lata recubierta, particularmente útil para usarse en un inhalador de dosis medida presurizada para el tratamiento de enfermedades respiratorias.
CONC2022/0012207A 2020-01-28 2022-08-26 Inhaladores de dosis medida presurizada que comprenden una formulación farmacéutica amortiguada CO2022012207A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20153973 2020-01-28
EP20214091 2020-12-15
PCT/EP2021/051669 WO2021151857A1 (en) 2020-01-28 2021-01-26 Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation

Publications (1)

Publication Number Publication Date
CO2022012207A2 true CO2022012207A2 (es) 2022-11-08

Family

ID=74285492

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0012207A CO2022012207A2 (es) 2020-01-28 2022-08-26 Inhaladores de dosis medida presurizada que comprenden una formulación farmacéutica amortiguada

Country Status (16)

Country Link
US (1) US20230347080A1 (es)
EP (1) EP4096623A1 (es)
JP (1) JP2023511615A (es)
KR (1) KR20220133193A (es)
CN (3) CN113244490A (es)
AU (1) AU2021213883A1 (es)
BR (1) BR112022012361A2 (es)
CA (1) CA3163599A1 (es)
CL (1) CL2022002008A1 (es)
CO (1) CO2022012207A2 (es)
GB (1) GB2593283B (es)
GE (1) GEP20247594B (es)
IL (1) IL294804A (es)
MX (1) MX2022008440A (es)
PE (1) PE20221867A1 (es)
WO (1) WO2021151857A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024033941A1 (en) * 2022-08-10 2024-02-15 Cipla Limited A pharmaceutical composition of salbutamol and pharmaceutical green propellant

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ306280A (en) 1995-04-14 1999-07-29 Glaxo Wellcome Inc Metered dose inhaler for salmeterol
BR0015884A (pt) 2000-05-22 2003-07-08 Chiesi Farma Spa Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados
EP1241113A1 (en) * 2001-03-12 2002-09-18 CHIESI FARMACEUTICI S.p.A. Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein
MEP30108A (en) 2002-03-01 2010-06-10 Chiesi Farmaceutici S P Formoterol superfine formulation
US9308199B2 (en) 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
CN1301747C (zh) * 2004-11-30 2007-02-28 深圳市海王英特龙生物技术股份有限公司 一种蛋白药物微囊及其吸入性气雾剂
FR2895260B1 (fr) * 2005-12-23 2009-02-20 Servier Lab Nouvelle composition pharmaceutique a base d'huile essentielle pour pulverisation nasale et/ou buccale
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
AU2014375301B2 (en) * 2013-12-30 2020-03-26 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
EA033228B1 (ru) * 2013-12-30 2019-09-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Находящаяся под давлением стабильная аэрозольная композиция комбинации гликопиррония бромида и формотерола в форме раствора
WO2016018892A1 (en) * 2014-07-29 2016-02-04 3M Innovative Properties Company Method of preparing a pharmaceutical composition
CA3007050C (en) * 2015-12-04 2020-12-08 Mexichem Fluor S.A. De C.V. Pharmaceutical composition comprising a formoterol compound
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
ES2968453T3 (es) 2016-09-19 2024-05-09 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
JP6781832B2 (ja) * 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
GB2554091A (en) * 2016-09-19 2018-03-28 Mexichem Fluor Sa De Cv Pharmaceutical composition
GB2558191A (en) * 2016-09-19 2018-07-11 Mexichem Fluor Sa De Cv Pharmaceutical composition
GB2554088A (en) * 2016-09-19 2018-03-28 Mexichem Fluor Sa De Cv Pharmaceautical composition
CN112203649A (zh) * 2018-06-07 2021-01-08 金德瓦药物控释有限公司 氟替卡松和维兰特罗制剂以及吸入器

Also Published As

Publication number Publication date
AU2021213883A1 (en) 2022-07-21
US20230347080A1 (en) 2023-11-02
KR20220133193A (ko) 2022-10-04
BR112022012361A2 (pt) 2022-09-06
CL2022002008A1 (es) 2023-02-24
GEP20247594B (en) 2024-02-12
CA3163599A1 (en) 2021-08-05
GB2593283B (en) 2023-09-13
EP4096623A1 (en) 2022-12-07
PE20221867A1 (es) 2022-12-02
MX2022008440A (es) 2022-08-02
GB202101048D0 (en) 2021-03-10
CN115003282A (zh) 2022-09-02
CN113244490A (zh) 2021-08-13
JP2023511615A (ja) 2023-03-20
GB2593283A (en) 2021-09-22
CN117599290A (zh) 2024-02-27
IL294804A (en) 2022-09-01
WO2021151857A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
CL2022002235A1 (es) Inhaladores dosificadores presurizados que comprenden una formulación farmacéutica amortiguada
CY1122851T1 (el) Υπερλεπτο σκευασμα φορμοτερολης
AR098982A1 (es) Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol
CO6541628A2 (es) Terapia combinada para enfermedad pulmonar obstructiva crónica (epoc)
Virchow et al. Importance of inhaler devices in the management of airway disease
Abdelrahim et al. In-vitro characterisation of the nebulised dose during non-invasive ventilation
MX9207200A (es) Formulacion farmaceutica en aerosol, bote para suministrar dicha formulacion e inhalador de dosis dosificada que comprende dicho bote.
MX9207205A (es) Formulacion farmaceutica en aerosol, bote para suministrarar dicha formulacion e inhalador de dosis dosificada que comprende dicho bote.
AR098983A1 (es) Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol
PE20011323A1 (es) Formulaciones farmaceuticas en solucion estable para inhaladores presurizados con medicion de dosis
CO2022012207A2 (es) Inhaladores de dosis medida presurizada que comprenden una formulación farmacéutica amortiguada
CL2023000998A1 (es) Formulación farmacéutica para inhalador presurizado de dosis medidas
NZ599900A (en) Pharmaceutical suspension aerosol formulations for use in metered dose inhalers
CY1117596T1 (el) Φαρμακευτικeς συνθeσεις αερολyματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης
CO5690570A2 (es) Nueva combinacion sinergistica que comprende roflumilast y formoterol
Bisgaard Automatic actuation of a dry powder inhaler into a nonelectrostatic spacer
BR112014008601A2 (pt) fabricação de tubos de aerossol para insumos medicinais
PE20011271A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
NZ591174A (en) Metered dose inhaler
US20170273991A1 (en) Treatment of congestion using steroids and adrenergics
PE20240807A1 (es) Composiciones, metodos y sistemas para la administracion de farmacos en aerosol
Anderson et al. Aerosolized drug delivery in awake and anesthetized children to treat bronchospasm
US20230302233A1 (en) Edta for treatment of cystic fibrosis and other pulmonary diseases and disorders
US20230271770A1 (en) Anti-Viral Pharmaceutical Formulations Administered Via Devices for Lung Targeted Delivery
BR112022010188A2 (pt) Formulação farmacêutica de solução de aerossol, lata de aerossol, inaladores pressurizados de dose calibrada e uso da referida formulação